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AbsTrACT
background Serrated polyposis syndrome (SpS) is 
a clinical entity characterised by large and/ormultiple 
serrated polyps throughout the colon and increased 
risk for colorectal cancer (CrC). the basis for SpS 
genetic predisposition is largely unknown. Common, 
low- penetrance genetic variants have been consistently 
associated with CrC susceptibility, however, their role in 
SpS genetic predisposition has not been yet explored.
Objective the aim of this study was to evaluate if 
common, low- penetrance genetic variants for CrC risk 
are also implicated in SpS genetic susceptibility.
Methods A case- control study was performed in 219 
SpS patients and 548 asymptomatic controls analysing 
65 CrC susceptibility variants. A risk prediction model for 
SpS predisposition was developed.
results Statistically significant associations with SpS 
were found for seven genetic variants (rs4779584-
GREM1, rs16892766-EIF3H, rs3217810-CCND2, 
rs992157-PNKD1/TMBIM1, rs704017-ZMIZ1, 
rs11196172-TCF7L2, rs6061231-LAMA5). the GREM1 
risk allele was remarkably over- represented in SpS 
cases compared with controls (or=1.573, 1.21–2.04, 
p value=0.0006). A fourfold increase in SpS risk was 
observed when comparing subjects within the highest 
decile of variants (≥65) with those in the first decile 
(≤50).
Conclusions Genetic variants for CrC risk are also 
involved in SpS susceptibility, being the most relevant 
ones rs4779584-GREM1, rs16892766-EIF3H and 
rs3217810-CCND2.
InTrOduCTIOn
Colorectal cancer (CRC) is currently one of the 
most common neoplasms in developed countries, 
and it represents the second most fatal malignancy 
after lung cancer.1 This neoplasm is developed from 
different precursor lesions, including conventional 
adenomas and serrated polyps. This heterogeneity 
drives the progression to carcinoma through distinct 
pathways.2 While most CRC progress through the 
adenoma–carcinoma sequence, serrated polyps, 
previously known as hyperplastic polyps, are also 
considered precursor lesions with an alternative 
pathway to CRC.3 The term serrated polyp refers 
to a lesion with a serrated or ‘sawtooth’ appearance 
of the colonic crypts at microscopy. On the other 
hand, the risk of developing CRC is influenced by 
both environmental and genetic factors. Part of 
this germline CRC predisposition is already known 
including both rare, high- penetrance and common, 
low- penetrance genetic variants.4 Genome- wide 
association studies (GWAS) have been conducted 
since 2007 and have identified ~130 common, 
low- penetrance genetic variants associated with 
CRC risk.5
Interestingly, prior studies have evaluated 
the association between GWAS- identified SNPs 
linked to CRC susceptibility and polyp subtypes, 
including adenomas, serrated polyps and advanced/
non- advanced polyps but not the association with 
serrated polyposis syndrome (SPS).6–9
SPS is a condition characterised by the devel-
opment of large and/or multiple serrated polyps 
throughout the colon and increased risk for CRC. 
The prevalence of CRC in patients with SPS has 
been estimated to range between 15% and 35%.3 10 
In order to help in identifying this clinical entity, 
the WHO established in 2010 the following criteria 
defining SPS as the presence of (I) at least five 
serrated polyps proximal to the sigmoid colon, of 
which two measure at least 10 mm in diameter and/
or (II) any number of serrated polyps occurring 
proximal to the sigmoid colon in an individual who 
has a first- degree relative with SPS and/or (III) more 
than 20 serrated polyps spread throughout the 
colon.11 Despite recent developments in sequencing 
technologies, the genetic aetiology of SPS remains 
largely unknown. The only proposed gene for 
germline SPS predisposition is RNF43, which 
would explain a small proportion of SPS cases.12–15
Keeping in mind that serrated polyps are consid-
ered CRC precursor lesions and considering 
that SPS confers a relatively high risk for CRC, 
the current study aims to test if common, low- 
penetrance genetic variants for CRC risk are also 
involved in the predisposition to SPS.
MATerIAls And MeThOds
study population
Our study comprised 219 Spanish patients ascer-
tained in high- risk clinics for CRC that fulfilled 
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the SPS clinical criteria.11 They included 130 men (59.36%) 
and 89 women (40.63%) aged between 20–78 (mean age 
54.62±11.08 years old). Presence of conventional adenomas 
in SPS patients was frequent (around 70%). We also included 
548 asymptomatic controls from the Barcelona CRC screening 
programme with a positive faecal immunochemical test but 
a negative colonoscopy showing no relevant findings related 
to CRC risk. The control group included 269 men (49.08%) 
and 279 women (50.92%), aged between 50–69 (mean age 
59.49±5.57 years old). Cases and controls included in this study 
were negative for a family history of hereditary or familial CRC or 
adenomatous polyposis (ie, ≥2 first- degree relatives with CRC/
adenomatous polyposis or one first- degree relative diagnosed 
before the age of 60). DNA was obtained from frozen peripheral 
blood by standard extraction procedures for all samples. RNF43 
mutations were excluded in the cases cohort. Mutations in other 
high- penetrance CRC genes such as MUTYH could not be ruled 
out although their contribution may be considered scarce since 
cases did not present a relevant family history for hereditary 
or familial CRC or adenomatous polyposis. Written informed 
consent was obtained from all individuals.
snP genotyping and quality control
Sixty- five SNPs previously associated with CRC susceptibility 
were selected and genotyped in all available DNA samples. 
SNPs were selected from previous GWAS published before 
mid-2017 ( www. ebi. ac. uk/ gwas/, GWAS Catalogue). Geno-
typing was performed with the Biomark 96.96 Genotyping 
dynamic array (Fluidigm, San Francisco, CA, USA) and TaqMan 
assays (Thermo Fisher Scientific, Waltham, MA, USA). Data 
quality was assessed using the Fluidigm SNP Genotyping Anal-
ysis and PLINK softwares. Samples and SNPs with genotyping 
success rate below 90% were removed from subsequent analyses 
(including rs7229639, rs3764482). One SNP was monomor-
phic and was also eliminated (rs10904849). In order to further 
test for genotyping quality, five samples were duplicated and 
genotype concordance was 100%. Deviation of the genotype 
frequencies in the controls from those expected under Hardy- 
Weinberg equilibrium (HWE) was assessed by the χ2 test (1df). 
Each SNP was in HWE (p value >0.01) in controls (data not 
shown), thereby excluding the possibility of genotyping artefacts 
and any hidden population stratification. After quality filtering, 
the final available dataset comprised 741 samples (215 cases and 
526 controls) and 62 SNPs. The overall genotyping success rate 
in the remaining individuals was 99.07%.
statistical analysis
Logistic regression analysis was used to evaluate the association 
between each SNP and SPS risk under an additive model. The 
total number of risk alleles was calculated for all samples and 
coded as 0, 1 or 2 for each SNP assuming an additive genetic 
effect. Two- sided t- test was applied to compare the mean 
number of risk alleles between cases and controls. Further-
more, an additive genetic risk score (GRS) was developed by 
using a general linear model to assess for genetic susceptibility. 
GRS was defined as the count of risk alleles across all available 
SNPs. An unweighted GRS was preferred. A weighted genetic 
risk score was also tested, using the originally published log- ORs 
as weights. Since the results were essentially the same, and the 
weights may be biassed due to the winner’s course effect, we 
opted to use the unweighted score. All statistical tests were two- 
sided, and p values <0.05 were considered statistically signifi-
cant. All analyses were performed using PLINK v1.09 (V.3.4.1). 
Bonferroni correction was used for multiple testing adjustment 
(α adjusted=0.05/62=8.06×10−4).
resulTs
Association tests for individual snPs
A total of 215 SPS patients and 526 controls were successfully 
genotyped for 62 SNPs previously linked with genetic suscepti-
bility to CRC. First, the frequency of CRC risk alleles between 
SPS cases and controls was compared and those significantly 
enriched in the SPS cohort were detected. Results are shown in 
table 1. Seven CRC SNPs showed statistically significant associa-
tions with SPS (rs992157, rs16892766, rs704017, rs11196172, 
rs3217810, 4779584, rs6061231) and these genetic associa-
tions were in the same direction as previously reported for CRC 
susceptibility. Despite being not significant, most remaining 
SNPs (42/52), showed ORs in the same directions as those previ-
ously described in the literature for CRC susceptibility.
Genetic risk score model
The presence of higher number of CRC risk alleles in the SPS 
cohort when compared with controls was also evaluated. The 
distribution of risk by allele number for the 62 genotyped SNPs 
is displayed in figure 1, both for cases and controls. The distri-
bution of risk alleles followed a normal distribution in both SPS 
cases and controls with a shift towards a higher number of risk 
alleles in affected individuals consistent with a cumulative impact 
of CRC risk alleles on SPS predisposition. The mean number 
of risk alleles in control individuals was 56.20 compared with 
57.46 in SPS cases and there was a statistically significant differ-
ence in the mean number of risk alleles between SPS cases and 
controls (difference: −1.26; two- sided t- test p value=0.0016).
Next, a GRS was calculated for SPS cases and controls when 
carrying an increasing number of CRC risk alleles. The median 
number of risk alleles in controls, 56, was considered as refer-
ence. SPS cases and controls were grouped considering subjects 
carrying ≤45 risk alleles and ≥65 alleles, because of the small 
number of subjects at these extremes. The risk score was higher 
in the SPS group compared with the control cohort (OR=1.05, 
95% CI 1.02 to 1.09, p value=0.0019). We observed that there 
was a twofold increase in SPS risk for subjects in the highest 
quintile of risk alleles (≥62) compared with those in the first 
quintile (≤53) (OR=2.16, 95% CI 1.29 to 3.63, p=0.0034). 
Additionally, a fourfold increase in SPS risk was detected for 
subjects in the highest decile of risk alleles (≥65), compared with 
those in the first decile (≤50) (OR=4.24, 95% CI 1.76 to 10.21, 
p value=0.0013). As shown in figure 1, the increase in risk per 
allele was linear, indicating the independent additive contribu-
tion of each allele to SPS risk.
dIsCussIOn
The association of 65 common, low- penetrance CRC suscepti-
bility variants in SPS development was assessed in a cohort of 
768 samples (219 SPS cases and 548 controls) in order to check 
if common, low- penetrance genetic variants for CRC risk were 
also involved in SPS genetic susceptibility. Our results showed 
statistically significant association of seven CRC genetic vari-
ants with SPS (rs992157, rs16892766, rs704017, rs11196172, 
rs3217810, rs4779584 and rs6061231).
Among the detected SPS genetic associations, the most signif-
icant corresponded to rs4779584. The T risk allele frequency 
was remarkably higher in SPS cases (25%) than in controls 
(17%) (OR=1.573, 1.21 to 2.04, p value=0.0006). This associ-
ation remained statistically significant even after multiple testing 
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Table 1 Case- control association results obtained by logistic regression analyses
snP* region nearby gene Variant type risk allele
rAF cases/
controls Or 95% CI P value
rs12080929 1p33 SLC5A9 Intronic variant T 0.73/0.71 1.086 (0.85 to 1.39) 0.5093
rs72647484 1p36.12 CDC42/WNT Intergenic variant C 0.08/0.08 1.096 (0.72 to 1.66) 0.6656
rs10911251 1q25.3 LAMC1 Intronic variant A 0.58/0.59 0.9767 (0.78 to 1.23) 0.8409
rs6691170 1q41 DUSP10 Intergenic variant T 0.34/0.36 0.9123 (0.72 to 1.15) 0.4376
rs11903757 2q32.3 NABP1 Intergenic variant C 0.13/0.15 0.8341 (0.61 to 1.15) 0.2653
rs992157 2q35 PNKD/TMBIM1 Intronic variant A 0.58/0.5 1.36 (1.09 to 1.7) 0.007454
rs11676348 2q35 CXCR2 Intergenic variant T 0.49/0.54 0.8345 (0.67 to 1.03) 0.09742
rs812481 3p14.1 LRIG1 Intronic variant G 0.53/0.52 1.022 (0.82 to 1.28) 0.8472
rs35360328 3p22.1 CTNNB1 intergenic variant A 0.14/0.14 0.9986 (0.72 to 1.38) 0.9931
rs10936599 3q26.2 TERC Synonymous variant C 0.78/0.75 1.174 (0.89 to 1.54) 0.2474
rs7136702 4q13.2 LARP4/DIP2B Intergenic variant T 0.32/0.34 0.9124 (0.72 to 1.16) 0.4501
rs3987 4q26 NDST3 Intergenic variant G 0.45/0.46 0.9761 (0.78 to 1.22) 0.831
rs2736100 5p15.33 TERT Intronic variant A 0.5/0.52 0.9495 (0.76 to 1.19) 0.6472
rs647161 5q31.1 PITX1 Intronic variant A 0.73/0.69 1.196 (0.94 to 1.52) 0.1458
rs1321311 6p1.2 CDKN1A Intergenic variant A 0.29/0.27 1.086 (0.84 to 1.4) 0.527
rs4711689 6p21.1 TFEB Intronic variant A 0.54/0.54 1.01 (0.81 to 1.27) 0.9282
rs11987193 8p12 DUSP4 Intergenic variant C 0.7/0.74 0.8091 (0.63 to 1.05) 0.1055
rs16892766 8q23.3 EIF3H Intergenic variant C 0.08/0.05 1.686 (1.09 to 2.62) 0.01959
rs6469656 8q23.3 EIF3H Intragenic variant A 0.9/0.89 1.112 (0.78 to 1.58) 0.5505
rs6983267 8q24.21 MYC Non- coding transcript variant/intronic 
variant
G 0.54/0.51 1.099 (0.88 to 1.37) 0.4035
rs719725 9p24 TPD52L3/UHRF2 Intronic variant A 0.62/0.58 1.198 (0.95 to 1.51) 0.1215
rs10795668 10p14 ARN5SP299/GATA3 Intronic variant A 0.3/0.33 0.8803 (0.69 to 1.12) 0.2995
rs704017 10q22.3 ZMIZ1- AS1 Intronic variant G 0.57/0.5 1.307 (1.04 to 1.64) 0.02218
rs1035209 10q24.2 ABCC2/MRP2 Intergenic variant T 0.16/0.16 0.9457 (0.7 to 1.28) 0.7188
rs11190164 10q24.2 SLC25A28 Intergenic variant G 0.2/0.23 0.8207 (0.62 to 1.08) 0.1657
rs11196172 10q25.2 TCF7L2 Intronic variant A 0.11/0.17 0.648 (0.46 to 0.91) 0.01186
rs12241008 10q25.2 VTI1A Intronic variant C 0.11/0.09 1.272 (0.87 to 1.86) 0.2129
rs4246215 11q12.2 FEN1 3'-UTR variant T 0.3/0.33 0.8561 (0.67 to 1.09) 0.2136
rs174537 11q12.2 MYRF Intronic variant G 0.7/0.67 1.161 (0.91 to 1.48) 0.226
rs1535 11q12.2 FADS2 Intronic variant A 0.69/0.66 1.168 (0.92 to 1.49) 0.206
rs174550 11q12.2 FADS1 Intronic variant T 0.69/0.67 1.124 (0.88 to 1.43) 0.3422
rs3824999 11q13.4 POLD3 Intronic variant G 0.53/0.49 1.146 (0.92 to 1.43) 0.2257
rs3802842 11q23.1 COLCA1/COLCA2 Intronic variant C 0.26/0.26 0.9952 (0.78 to 1.28) 0.9696
rs2238126 12p13.2 ETV6 Intronic variant G 0.14/0.16 0.8391 (0.61 to 1.15) 0.2764
rs10849432 12p13.31 CD9 Intronic variant T 0.88/0.88 1.065 (0.75 to 1.52) 0.7295
rs11064437 12p13.31 SPSB2 Splice acceptor variant C 1/0.99 2.453 (0.57 to 10.48) 0.2256
rs3217901 12p13.32 CCND2 Intronic variant G 0.38/0.34 1.162 (0.92 to 1.47) 0.2046
rs10774214 12p13.32 CCND2 Intronic variant T 0.37/0.35 1.125 (0.89 to 1.42) 0.3242
rs3217810 12p13.32 CCND2 Intronic variant T 0.12/0.08 1.686 (1.16 to 2.45) 0.006237
rs11169552 12q13.12 DIP2B/ATF1 Intergenic variant C 0.76/0.76 0.9557 (0.74 to 1.24) 0.7319
rs3184504 12q24.12 SH2B3 Mis- sense variant C 0.58/0.56 1.066 (0.85 to 1.33) 0.5737
rs59336 12q24.21 TBX3 Intronic variant T 0.54/0.52 1.092 (0.87 to 1.37) 0.4528
rs73208120 12q24.22 NOS1 Intronic variant G 0.06/0.05 1.053 (0.64 to 1.74) 0.8393
rs4444235 14q22.2 BMP4 Intergenic variant C 0.56/0.55 1.036 (0.83 to 1.3) 0.7544
rs1957636 14q22.2 BMP4 Intronic variant T 0.41/0.4 1.044 (0.83 to 1.31) 0.7078
rs17094983 14q23.1 RTN1 Intergenic variant G 0.86/0.86 0.9959 (0.72 to 1.38) 0.9803
rs4779584 15q13.3 GREM1 Intergenic variant T 0.25/0.17 1.573 (1.21 to 2.04) 0.0006432
rs9929218 16q22.1 CDH1 Intronic variant G 0.72/0.69 1.169 (0.91 to 1.49) 0.212
rs16941835 16q24.1 FOXL1 Intergenic variant C 0.17/0.18 0.9193 (0.68 to 1.24) 0.5842
rs12603526 17q13.3 NXN Intronic variant C 0.01/0.01 1.368 (0.45 to 4.13) 0.5786
rs4939827 18q21.1 SMAD7 Intronic variant T 0.56/0.55 1.063 (0.85 to 1.33) 0.5909
rs12970291 18q22.3 TSHZ1 Intergenic variant A 0.04/0.03 1.127 (0.6 to 2.12) 0.7105
rs10411210 19q13.11 RHPN2 Intronic variant C 0.87/0.87 0.9811 (0.71 to 1.36) 0.9099
rs2241714 19q13.2 B9D2 Mis- sense variant/2 kb upstream 
variant
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snP* region nearby gene Variant type risk allele
rAF cases/
controls Or 95% CI P value
rs1800469 19q13.2 TGFB1 2 kb upstream variant/0.5 kb 
downstream variant
G 0.67/0.65 1.102 (0.87 to 1.4) 0.4215
rs2423279 20p12.3 HAQ1 Intergenic variant C 0.28/0.31 0.8595 (0.67 to 1.1) 0.2333
rs961253 20p12.3 BMP2 Intergenic variant A 0.34/0.32 1.085 (0.86 to 1.37) 0.4941
rs4813802 20p12.3 BMP2 Regulatory region variant? G 0.36/0.32 1.216 (0.96 to 1.54) 0.1046
rs6066825 20q13.13 PREX1 Intronic variant A 0.6/0.58 1.113 (0.89 to 1.39) 0.3445
rs6061231 20q13.33 LAMA5 Intergenic variant C 0.78/0.72 1.412 (1.08 to 1.85) 0.01189
rs4925386 20q13.33 LAMA5 Intronic variant C 0.73/0.68 1.261 (0.98 to 1.62) 0.06688
rs5934683 Xp22.2 SHROOM2 Intronic variant C 0.59/0.61 0.9276 (0.71 to 1.22) 0.5873
Association results for 216 SPS cases and 526 controls. Results are based on the reported risk allele from previous CRC GWAS. Statistically significant associations are denoted in 
bold (p value <0.05).
*SNPs with genotyping success rate below 90% were removed from subsequent analyses (including rs7229639, rs3764482). We also removed a monomorphic SNP 
(rs10904849).
CRC, colorectal cancer; GWAS, genome- wide association studies; RAF, risk allele frequency; SPS, serrated polyposis syndrome; UTR, untranslated region.
Table 1 Continued
Figure 1 Genetic risk score. Distribution of risk by allele number for the 62 SNps genotyped. the presence of multiple CrC risk alleles is displayed for SpS 
cases (bold bars) and controls (stripped bars). CrC, colorectal cancer; SpS, serrated polyposis syndrome
corrections. This SNP maps to chromosomal region 15q13.3, is 
intergenic and lies between SCG5 and GREM1. It was previously 
suggested that this variant captures two independent association 
signals represented by rs16969681 and rs11632715 upstream 
of GREM1.16 The rs16969681 variant lies upstream of GREM1 
and is close to a regulatory element that acts as an allele- specific 
GREM1 enhancer. The rs16969681 risk allele differentially 
binds with a higher affinity the intestine- specific transcription 
factor CDX2 and the Wnt effector TCF7L2 producing a stronger 
GREM1 expression and promoting tumourigenesis.17 Note-
worthy, a 40 kb duplication upstream of this gene was previously 
linked with increased GREM1 expression in individuals with 
hereditary mixed polyposis.18 This clinical entity shows some 
overlap with SPS since patients develop polyps of multiple and 
mixed morphologies including serrated lesions, Peutz- Jeghers 
polyps, juvenile polyps, conventional adenomas and CRC 
(OMIM # 601228). Moreover, this genetic variant had been 
linked with serrated polyps in previous studies.7 9
Additionally, our results show that rs16892766 at 8q23.3 
is associated with SPS susceptibility. Previous fine mapping in 
this region and functional analysis identified rs16888589 as 
the potential effector of this association through increasing the 
expression of EIF3H, promoting carcinogenesis.19 Besides, we 
also detected an association with SPS for rs3217810 at 12p13.32 
located in the intron of CCND2, a cyclin involved in cell cycle 
G1/S transition.20 Both SNPs had been previously linked with 
serrated polyps.9
Further novel associations with SPS were also detected in 
our cohort for rs992157 (2q35, PNKD/TMBIM1), rs704017 
(10q22.3, ZMIZ1), rs11196172 (10q25.2, TCF7L2) and 
rs6061231 (20q13.33, LAMA5). Interestingly, rs11196172 was 
previously associated with a higher TCF7L2 expression.21 As 
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previously commented, high levels of activated TCF7L2 increase 
GREM1 expression. Therefore, the rs11196172 risk allele may 
also have an impact on GREM1 expression. It is also important 
to highlight that the 20q13.33 region harbouring LAMA5 may 
be suggested as relevant for SPS susceptibility since two vari-
ants from that locus showed either a significant (rs6061231) or 
borderline significant association (rs4925386).
Regarding the results of our polygenic risk model, the distri-
bution of CRC risk alleles follows a normal distribution in 
both SPS cases and controls, with a shift towards a higher allele 
number in SPS cases. These results show an enrichment of CRC 
susceptibility variants in the SPS cohort, therefore suggesting 
those variants may play a role in mediating CRC risk through 
serrated lesions and SPS predisposition. A similar study from our 
group identified CRC risk variants related to advanced adenoma, 
implying that part of CRC risk is mediated through susceptibility 
to this other polyp type.8
It should be noted that this study corresponds to the first 
analysis of common, low- penetrance CRC risk variants in a SPS 
cohort. However, we are aware that our results are preliminary 
and this study has several limitations including limited sample 
size, lack of environmental data or no replication in an inde-
pendent SPS cohort. Therefore, further studies are needed to 
confirm our findings. On the other hand, specific GWAS for SPS 
susceptibility or serrated polyps are needed to further charac-
terise more precisely the germline predisposition architecture of 
this clinical entity.
In summary, our study suggests that some CRC risk genetic vari-
ants could also be involved in SPS susceptibility. The rs4779584 
variant, near GREM1, seems to be the most important effector of 
the common, low- penetrance SPS susceptibility identified so far. 
Likewise, rs16892766, and rs3217810 could be relevant since 
they have been identified linked to serrated lesions in previous 
studies. There are potential implications of our study in the near 
future. CRC SNPs predisposing to SPS and new SPS SNPs could 
be used to identify a subgroup of individuals with increased 
disease risk and modulate population- based CRC- prevention 
measures.
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